|Articles|April 14, 2004
FDA says Aldara "approvable" for superficial basal cell carcinoma Tx
Source: www.pharmalive.com 3M has received an ?approvable? letter from the FDA in response to its supplemental new drug application on Aldara (imiquimod cream), 5 percent, for treatment of superficial basal cell carcinoma, a common form of non-melanoma skin cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinique's Daily Calm Merges Clinical Efficacy with Color Cosmetics for Sensitive Skin
2
Clear Health Launches Topical Isotretinoin Acne Treatment Without iPLEDGE Requirements
3
Systematic Comorbidity Screening in Atopic Dermatitis: Insights From Adam Friedman, MD, at RAD 2026
4
Familiar Faces at Revolutionizing Atopic Dermatitis 2026
5










